NCT04173286 (CASCAD) is a clinical trial of antibiotherapy in Acute Cholangitis, sponsored by Nantes University Hospital.

Who is sponsoring NCT04173286?

NCT04173286 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT04173286?

Interventions in NCT04173286: antibiotherapy.

What condition does NCT04173286 study?

NCT04173286 studies Acute Cholangitis.

Is NCT04173286 still recruiting?

NCT04173286 is currently status unknown. Last updated 21 November 2019.

Last reviewed 2019-11-21 · How we verify

NCT04173286: CASCAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Is Short Antibiotherapy Duration After Drainage Suitable for Patients Admitted in Intensive Care Medicine With a Severe Acute Cholangitis?

Status unknown Last updated 21 November 2019

What this trial tests

trial testing antibiotherapy in Acute Cholangitis in 80 participants. Status unknown.

Timeline

7 October 2019

Primary endpoint
1 January 2020

1 January 2021

Quick facts

Lead sponsor	Nantes University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	80
Start date	7 October 2019
Primary completion	1 January 2020
Estimated completion	1 January 2021
Sites	1 location across France

Drugs / interventions tested

antibiotherapy

Conditions studied

Acute Cholangitis — all drugs for Acute Cholangitis →

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Acute Cholangitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute cholangitis (AC) occurs when biliary stenosis, due to various benign causes (often gallstones) or the presence of a tumour, leads to cholestasis and biliary infection. AC is a life-threatening infection if not diagnosed and treated in time, its mortality ranges from 1.4% to 5.2%. AC can be classified into different stages of severity depending on organ failure. A severity classification has been proposed by the Asian recommendations of Tokyo 2013: Grade I (Benin), Grade II (Moderate) and Grade III (Severe). AC treatment includes endoscopic or percutaneous bile drainage in combination with systemic antibiotic treatment. It is currently recommended that patients with severe CA (Grade III) have biliary drainage within 24 hours, although it has not been shown to improve their survival. The emergence of antibiotic-resistant germs, which is a public health issue, calls for reasonable and considered use of antibiotics. Reducing the duration of antibiotic therapy is a fundamental measure of antimicrobial management and antibiotics sparing. 7 to 10 days of antibiotic treatment is common in the treatment of CA. A 14-day treatment is recommended in case of associated bacteremia. A recent study of 263 patients showed that reducing the duration of antibiotic therapy to less than 7 days in patients with CA associated with bacteremia with effective drainage does not increase the risk of recurrence or mortality at 30 days. However, this study was monocentric retrospective and compared groups that were unbalanced in terms of CA severity. The optimal duration of antibiotic therapy in the treatment of CA in critically ill patients hospitalized in intensive care remains poorly known. The main purpose of this study is to compare short antibiotic therapy with long antibiotic therapy in terms of mortality in patients with AC admitted in intensive care unit (ICU).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Cholangitis

Currently open trials in the same condition.

NCT07407491 — Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis · Phase 2 · recruiting
NCT02601417 — The Necessity of Bile Cultures in Patients With Acute Cholangitis · NA · active not recruiting

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04173286 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 21 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04173286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing